During the past decade, The Third Hospital of Changsha conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 2 clinical trials were completed, i.e. on average, 15.4% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Third Hospital of Changsha" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 2 trials sponsored, "The Third Xiangya Hospital of Central South University" with 2 trials sponsored, "Bayer" with 1 trials sponsored and "BioRegen Biomedical (CHangzhou) Co., Ltd" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Third Hospital of Changsha" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Ankang City Central Hospital" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Beihua University" with 1 trials as a collaborator and "Beijing Chuiyangliu Hospital(Beijing Minimally Invasive Hospital)" with 1 trials as a collaborator. Other collaborators include 53 different institutions and companies that were collaborators in the rest 63 trials.

According to Clinical.Site data, the most researched conditions in "The Third Hospital of Changsha" are "Acute Coronary Syndrome" (2 trials), "Atrial Fibrillation" (2 trials), "Heart Failure" (2 trials), "Type 2 Diabetes Mellitus (T2DM)" (2 trials) and "Accurate Medication" (1 trials). Many other conditions were trialed in "The Third Hospital of Changsha" in a lesser frequency.

Most popular intervention types in "The Third Hospital of Changsha" are "Drug" (11 trials), "Device" (2 trials), "Behavioral" (1 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Empagliflozin" (2 trials), "Acarbose" (1 trials), "Apixaban" (1 trials) and "Apixaban matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Third Hospital of Changsha" are 13 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The Third Hospital of Changsha". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in The Third Hospital of Changsha, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in The Third Hospital of Changsha, 5 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".